Fig. 9

Effect of Momelotinib (Mom) on the expression of phospho and total STAT3, TIMP-1, 2 and 3, chemoresistant genes (ERCC1 and TUBB3), cancer stem cell markers (Oct4A, CD133) in OVCAR4 P cells treated with paclitaxel (pac) or cisplatin (cis). Effect of Momelotinib (1 μM) on a P-STAT3 (red) and T-STAT3 (red) expression after treatment with paclitaxel or cisplatin; b mRNA expression of TIMPs 1–3, c MMP-2 and MT1-MMP, d ERCC1, TUBB3 and e OCT4 and CD133 in OVCAR4 cells after treatment with paclitaxel only. P-STAT3 expression was evaluated by immunofluorescence. mRNA expression of TIMPs (1–3), MMP-2, MT1-MMP, ERCC1, TUBB3, OCT4A, CD133 was determined by qRT-PCR as described in Methods. Each experiment was repeated three times and was performed in triplicate. For immunofluorescence images, magnification was (20X); scale bar (in yellow) 20 μM. Significance was determined by one-way ANOVA *p > 0.05; **p > 0.01; ***p > 0.001 in OVCAR4 cells +/− treatment with paclitaxel or a combination of paclitaxel and Momelotinib